200~400% GROWTH
Amazing product gammaCore (nVNS technology) that is FDA approved for certain treatments. At the moment it's a medical device painkiller without the use of medication/drug. Helps avoid many drug-like side effects and inconveniences associated with injectable, inhaled, or pill-based medicines.
The same product and technology is being extended to explore other areas:
electrocore.com/future-developments/pipeline/
Other Positives:
Positive financial guidance for next quarter:
Full-year 2020 Revenue: electroCore anticipates that full-year 2020 revenue will be at the upper end of the previously announced guidance range of $3.3 million to $3.5 million, representing greater than 40% growth over full-year 2019 revenue of $2.4 million.
(globenewswire.com/news-release/2021/01/11/2156220/0/en/electroCore-Provides-Business-Update-and-Select-Financial-Guidance.html)
The same product and technology is being extended to explore other areas:
electrocore.com/future-developments/pipeline/
Other Positives:
- Scottish Health Technology recommendation (seekingalpha.com/news/3653075-electrocore-rallies-on-scottish-health-technology-recommending-gammacore-for-cluster-headache)
- 5 Analysts buy (tipranks.com/stocks/ecor/forecast)
- Centers for Medicare and Medicaid Services (“CMS”) validation (globenewswire.com/news-release/2021/01/19/2160526/0/en/electroCore-Inc-Announces-the-Establishment-of-a-Unique-Level-II-HCPCS-Code-for-Non-Invasive-Vagus-Nerve-Stimulator.html)
Positive financial guidance for next quarter:
Full-year 2020 Revenue: electroCore anticipates that full-year 2020 revenue will be at the upper end of the previously announced guidance range of $3.3 million to $3.5 million, representing greater than 40% growth over full-year 2019 revenue of $2.4 million.
(globenewswire.com/news-release/2021/01/11/2156220/0/en/electroCore-Provides-Business-Update-and-Select-Financial-Guidance.html)
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.